Physician profile
Michael Obrien
NPI 1851380968
$782.58
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.44 · 2020: $530 · 2021: $177.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kuros Biosciences USA, INC | $235.58 | 2020 | |
| Pacira Therapeutics, INC. | $188.67 | 2020-2021 | |
| Innovasis INC | $171.83 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $47.00 | 2021 | |
| Fidia Pharma USA INC. | $40.24 | 2019-2020 | |
| Abbott Laboratories | $37.41 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $19.46 | 2020 | |
| Smith+Nephew, INC. | $15.81 | 2019 | |
| Kci USA, INC. | $14.77 | 2019 | |
| Avanos Medical | $11.81 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.